Effect of short-term high-dose atorvastatin on systemic inflammatory response and myocardial ischemic injury in patients with unstable angina pectoris undergoing percutaneous coronary intervention

Chinese Medical Journal

Volumn 127, Issue 21, 2014, Pages 3732-3737

  Sun, Fei ^a   Yin, Zhao ^a   Shi, Quan Xing ^a   Zhao, Bei ^a   Wang, Shou Li ^a  

^a 306 HOSPITAL OF PLA   (China)

Author keywords

Atorvastatin; C reactive protein; Interleukin 6; Percutaneous coronary intervention

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE MB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN I;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNSTABLE ANGINA PECTORIS; AGED; ANGINA, UNSTABLE; CARDIAC MUSCLE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANGINA, UNSTABLE; ATORVASTATIN CALCIUM; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PERCUTANEOUS CORONARY INTERVENTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 84908412829     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20141199     Document Type: Article

References (38)

1. Pervaiz MH, Sood P, Sudhir K, Hermiller JB, Hou L, Hattori K, et al. Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. Circ Cardiovasc Interv 2012; 5: 150-156.
2. Inoue T, Kato T, Uchida T, Sakuma M, Nakajima A, Shibazaki M, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 2005; 46: 239-245.
3. Moohebati M, Falsoleiman H, Dehghani M, Fazlinezhad A, Daloee MH, Esmaeili H, et al. Serum inflammatory and immune marker response after bare-metal or drug-eluting stent implantation following percutaneous coronary intervention. Angiology 2011; 62: 184-190.
4. Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J 2009; 73: 615-621.
5. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011; 4: 1057-1066.
6. Woo JS, Kim W, Jang HH, Kim JB, Kim WS, Kim KS. Effect of platelet reactivity, endothelial function, and inflammatory status on outcomes in patients with stable angina pectoris on clopidogrel therapy. Am J Cardiol 2014; 113: 786-792.
7. Testa L, Van Gaal WJ, Biondi Zoccai GG, Agostoni P, Latini RA, Bedogni F, et al. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 2009; 102: 369-378.
8. van Klei WA, Buhre WF. Anti-inflammatory effects of perioperative statin therapy. Can J Anaesth 2012; 59: 516-521.
9. Ye Y, Zhao X, Zhai G, Guo L, Tian Z, Zhang S. Effect of high-dose statin versus low-dose statin plus ezetimibe on endothelial function: a meta-analysis of randomized trials. J Cardiovasc Pharmacol Ther 2012; 17: 357-365.
10. Girotra S, Murarka S, Migrino RQ. Plaque regression and improved clinical outcomes following statin treatment in atherosclerosis. Panminerva Med 2012; 54: 71-81.
11. Shalev V, Goldshtein I, Porath A, Weitzman D, Shemer J, Chodick G. Continuation of statin therapy and primary prevention of nonfatal cardiovascular events. Am J Cardiol 2012; 110: 1779-1786.
12. Ribeiro RA, Ziegelmann PK, Duncan BB, Stella SF, da Costa Vieira JL, Restelatto LM, et al. Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients. Int J Cardiol 2013; 166: 431-439.
13. Kim JS, Kim J, Choi D, Lee CJ, Lee SH, Ko YG, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv 2010; 3: 332-339.
14. Li XD, Yang YJ, Hao YC, Yang Y, Zhao JL, Dou KF, et al. Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis. Chin Med J 2013; 126: 1755-1760.
15. Tanaka H, Sukhova GK, Swanson SJ, Clinton SK, Ganz P, Cybulsky MI, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 1993; 88: 1788-1803.
16. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22: 1769-1776.
17. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug events And Reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175-181.
18. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-705.
19. Ndrepepa G, Braun S, Cassese S, Fusaro M, King L, Kastrati A, et al. C-reactive protein and prognosis in women and men with coronary artery disease after percutaneous coronary intervention. Cardiovasc Revasc Med 2013; 14: 264-269.
20. Niccoli G, Sgueglia GA, Latib A, Crea F, Colombo A; CACTUS Study Group. Association of baseline C-reactive protein levels with periprocedural myocardial injury in patients undergoing percutaneous bifurcation intervention: a CACTUS study subanalysis. Catheter Cardiovasc Interv 2014; 83: E37-E44.
21. Ozer N, Tangurek B, Firat F, Ozer S, Tartan Z, Ozturk R, et al. Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Heart Vessels 2008; 23: 75-82.
22. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl JMed 2008; 359: 2195-2207.
23. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
24. Hao PP, Chen YG, Wang JL, Ji WQ, Xue L, Liu XH, et al. Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease. Clin Exp Pharmacol Physiol 2010; 37: 496-500.
25. Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One 2012; 7: e34450.
26. Zhang BC, Li WM, Xu YW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol 2011; 27: 851-858.
27. Gordin J, Haider A, Swaminathan RV, Kim LK, Minutello RM, Bergman G, et al. Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention. Am J Cardiol 2012; 110: 1397-1404.
28. Veselka J, Zemánek D, Hájek P, Malý M, Adlová R, Martinkovičová L, et al. Effect of two-day atorvastatin pretreatment on long-term outcome of patients with stable angina pectoris undergoing elective percutaneous coronary intervention. Am J Cardiol 2011; 107: 1295-1299.
29. Jang Y, Zhu J, Ge J, Kim YJ, Ji C, Lam W. Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve asian patients with non-ST elevation acute coronary syndromes: a randomized study. J Cardiol 2014; 63: 335-343.
30. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003; 42: 1406-1411.
31. Lotrionte M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ, Valgimigli M, et al. Meta-analysis appraising high clopidogrel loading in patients undergoing perccutaneous coronary intervention. Am J Cardiol 2007; 100: 1199-1206.
32. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009; 119: 2758-2764.
33. Kinsella A, Raza A, Kennedy S, Fan Y, Wood AE, Watson RW. The impact of high-dose statin therapy on transendothelial neutrophil migration and serum cholesterol levels in healthy male volunteers. Eur J Clin Pharmacol 2011; 67: 1103-1108.
34. Puato M, Faggin E, Rattazzi M, Zambon A, Cipollone F, Grego F, et al. Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy. Stroke 2010; 41: 1163-1168.
35. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96: 24F-33F.
36. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM 2012; 105: 145-157.
37. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305: 2556-2564.
38. Nago N, Ishikawa S, Goto T, Kayaba K. Low cholesterol is associated with mortality from stroke, heart disease, and cancer: the Jichi Medical School Cohort Study. J Epidemiol 2011; 1: 67-74.